Here’s Why Alnylam Pharmaceuticals (ALNY) Declined
American Century Investments, an investment management company, released its second-quarter 2026 investor letter for the “American Century Investments Focused Dynamic Growth Fund”.
Alnylam Pharmaceuticals Inc. (ALNY)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Orbis Investment Management William B. Gray | 1,987,407 | $598,269,130 | +49% | 2.06% |
| 2. | D E Shaw D. E. Shaw | 1,104,109 | $332,369,932 | +5% | 0.16% |
| 3. | Deep Track Capital David Kroin | 825,000 | $248,349,750 | 3.61% | |
| 4. | AQR Capital Management Cliff Asness | 728,039 | $218,994,064 | -21% | 0.08% |
| 5. | Polar Capital Brian Ashford-Russell And Tim Woolley | 482,751 | $145,322,534 | +88% | 0.34% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $302.67 | 4 | $1,210.68 | 36 | 2024-10-17 | Filing | |
| $286.00 | 32 | $9,152.00 | 32 | 2024-08-29 | Filing | |
| $71.87 | 297,501 | $21,381,396.87 | 10,554,134 | 2017-05-31 | Filing | |
| $65.35 | 11,500 | $751,502.00 | 11,500 | 2017-05-30 | Filing | |
| $37.00 | 27,900 | $1,032,327.90 | 27,900 | 2016-10-13 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $302.65 | 17 | $5,145.05 | 1,582 | 2026-06-01 | Filing | |
| $300.72 | 495 | $148,856.40 | 1,599 | 2026-06-01 | Filing | |
| $299.87 | 1,222 | $366,441.14 | 2,094 | 2026-06-01 | Filing | |
| $298.91 | 1,175 | $351,219.25 | 3,316 | 2026-06-01 | Filing | |
| $297.71 | 921 | $274,190.91 | 4,491 | 2026-06-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 15,023,962 | $4,522,663,249 | 0.2% | |
| 2. | 11,144,846 | $3,354,715,611 | 0.4% | |
| 3. | 10,907,675 | $3,283,537,489 | 0.05% | |
| 4. | 9,750,699 | $2,935,115,324 | 0.41% | |
| 5. | 6,538,390 | $1,968,251,542 | 0.09% |
News See All
Raymond James Is Betting Big on These 2 ‘Strong Buy’ Stocks
The S&P 500 is now sitting just below its record high, with another strong earnings season helping stocks remain near their highs. The strength has...
Why Alnylam's Best Quarter Ever Didn't Come With a Richer Valuation
2026 has marked a significant turning point in biotech capital markets, not just a small comeback.
10 Best Growth Stocks With Highest Upside Potential
In this article, we will look at the 10 Best Growth Stocks With Highest Upside Potential.
What Offers Alnylam Pharmaceuticals (ALNY) Sustained Long-Term Growth?
Brown Advisory, an investment management company, released its “Brown Large-Cap Growth Strategy” for the first-quarter 2026 investor letter. A copy of the letter is available to download here.
10 Best Fundamentally Strong Stocks to Buy for Long Term
In this article, we will discuss: 10 Best Fundamentally Strong Stocks to Buy for Long Term.
10 Most Promising Long-Term Stocks to Buy According to Analysts
In this article, we will discuss the 10 Most Promising Long-Term Stocks to Buy According to Analysts.
12 Best AI Drug Discovery Stocks Hedge Funds Are Loading Up On
In this article, we will discuss: 12 Best AI Drug Discovery Stocks Hedge Funds Are Loading Up On.
10 Most Promising Healthcare Stocks According to Wall Street Analysts
In this article, we will look at the 10 Most Promising Healthcare Stocks According to Wall Street Analysts.
15 High-Growth Large-Cap Stocks to Invest In Now
In this article, we will discuss the 15 High-Growth Large-Cap Stocks to Invest In Now.
Hedge Fund Resource Center